Lingbin Meng

Lingbin Meng's work spans clinical and translational oncology, with particular attention to immunotherapy (immune checkpoint inhibitors) in cancers such as bladder, lung, liver, and head-and-neck cancer, alongside biomarker discovery for treatment response. Additional research covers oxidative stress and molecular mechanisms in conditions like Alzheimer's disease, diabetes, and cardiovascular injury, often involving pathways such as Nrf2 and ferroptosis. This researcher's output reflects a mix of real-world clinical outcome studies and mechanistic/molecular investigations.

Publication output rose to a peak around 2019-2021 but has notably slowed since 2022, with only a handful of publications per year in 2023-2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026